- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04562441
NPC - AXEL Study : Axitinib-Avelumab
AXEL: Axitinib-Avelumab Combination in Recurrent or Metastatic Nasopharyngeal Cancer: a Multicenter Phase 2 Trial
Nasopharyngeal cancer (NPC) is the most common head and neck cancer in South China and South East Asia. Worldwide, there are 80,000 incident cases and 50,000 deaths annually. In Hong Kong, NPC ranked as the tenth most common cancer in man. Up to 30% of NPC patients will develop recurrence or metastases after primary radiotherapy or chemoradiation. Platinum-based chemotherapy regimen has been the main stay of first line treatment for recurrent or metastatic NPC. However, the duration of response is short and currently there is no recommended standard second line chemotherapy. Axitinib is a highly potent and selective inhibitor of VEGF receptor. Selectively targeting a single growth factor receptor pathway provides the potential to rationally adjust dosages and combine drugs directed at specific parts of the pathway to minimize toxicity and achieve the optimum therapeutic benefit. In the phase 2 axitinib monotherapy in recurrent or metastatic NPC who failed at least one line of chemotherapy, the clinical benefit rate (CBR, complete response + partial response + stable disease) was 78.4% at 3 months but decreased to 43.2% at 6 months. However, the confirmed objective response rate (ORR) by RECIST was only 2.7% and unconfirmed ORR of 18.9%, with no complete response.Recently, the promising clinical activity of immune check point inhibitors has been demonstrated in NPC. The ORR was 25.9% (7 partial responses out of 27 patients) for single agent pembrolizumab, and 20.5% (including 1 complete response and 7 partial responses out of 44 patients) for single agent nivolumab,9 in recurrent or metastatic NPC who failed at least first line chemotherapy.
The combination of axitinib and avelumab has been studied in renal cell carcinoma (RCC). Based on the above promising and positive results in renal cell carcinoma (RCC) and head and neck squamous cell carcinomas (HNSCC), the investigators hypothesize that the combination of axitinib and avelumab in the second line setting of NPC will achieving a more complete, deep and durable response than either agent alone, without a significant increase in toxicity.
This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of the combination of axitinib and avelumab in recurrent or metastatic NPC patients who failed at least one line of platinum-based chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Anthony TC Chan, MD
- Phone Number: 3505 2119
- Email: anthony@clo.cuhk.edu.hk
Study Contact Backup
- Name: Edwin Pun HUI, MD
- Phone Number: 3505 2145
- Email: p_hui@clo.cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of nasopharyngeal carcinoma (NPC) (either at initial diagnosis or at recurrence).
- Available fresh or archival tumor tissue for biomarker study
- Patients with recurrent or metastatic NPC that has progressed following one line of prior platinum-based chemotherapy.
- Disease must be not amenable to potentially curative radiotherapy or surgery.
- At least one measurable lesion as defined by RECIST v1.1 that has not been previously irradiated.
- Age 18 or above;
- ECOG performance 0 or 1.
- Adequate bone marrow, renal and hepatic reserve.
Exclusion Criteria:
- Prior therapy with immune check point inhibitors or VEGF pathway inhibitors.
- Presence of local recurrence.
- Presence of neck lymph node recurrence invading vascular structure.
- Presence of central lung lesions involving major blood vessels.
- History of hemoptysis or epistaxis within 4 weeks.
- Preexisting uncontrolled hypertension defined as more than 140/90 mmHg despite adequate medical therapy.
- Gastrointestinal abnormalities, including inability to take oral medication or malabsorption syndrome.
- Concurrent use or anticipated need for treatment with known potent CYP3A4 inhibitors or CYP3A4 /CYP1A2 inducers.
- CNS metastases requiring systemic steroid
- Active autoimmune disease
- Pregnant or lactating female
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Axitinib and Avelumab
Axitinib: 5 mg bd po Day 1 to Day 28 Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks |
Axitinib: 5 mg bd po Day 1 to Day 28
Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Confirmed objective response rate (ORR)
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival (PFS)
Time Frame: 3 years
|
3 years
|
Overall survival (OS)
Time Frame: 3 years
|
3 years
|
6-month PFS rate
Time Frame: 6 months
|
6 months
|
OS rates at 12 months and 24 months
Time Frame: 2 years
|
2 years
|
Objective tumor response rate
Time Frame: 2 years
|
2 years
|
Disease control rate (DCR) at 12 and 24 weeks
Time Frame: 2 years
|
2 years
|
Time to tumor response (TTR)
Time Frame: 2 years
|
2 years
|
Duration of response (DR)
Time Frame: 2 years
|
2 years
|
Patient-Reported Outcomes (FACT-NP)
Time Frame: 2 years
|
2 years
|
Patient-Reported Outcomes (EQ-5D)
Time Frame: 2 years
|
2 years
|
Type, incidence, severity (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0)
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony Chan, MD, Department of Clinical Oncology, The Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NPC 033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent or Metastatic NPC
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingRecurrent or Metastatic NPCChina, Taiwan, Singapore
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic or Recurrent Lesions in the Spine | Metastatic or Recurrent Lesions in the PelvisUnited States
-
Chinese University of Hong KongCompleted
-
XinWuRecruitingMetastatic or Recurrent Gynecological TumorsChina
-
ITabMed Co., Ltd.Not yet recruitingRecurrent or Metastatic Solid Tumors
-
Sidney Kimmel Comprehensive Cancer Center at Johns...PapiVax Biotech, Inc.RecruitingHPV 16+ Recurrent or Metastatic CancerUnited States
-
MedImmune LLCCompletedRecurrent or Metastatic Solid TumorsUnited States, Australia
-
PharmaMatrix Holdings LtdUniversity of AlbertaRecruitingCancer: Recurrent and/or Metastatic Solid TumoursCanada
-
Beijng Immunoah Pharma Tech Co., Ltd.RecruitingRecurrent or Metastatic, Advanced Solid TumorsChina
-
UNICANCERBristol-Myers SquibbCompletedRecurrent and/or Metastatic Platinum-refractory SCCHNFrance
Clinical Trials on Axitinib
-
PfizerCompletedNeoplasmsPoland, United States, Spain
-
Peking University Cancer Hospital & InstituteUnknownAdvanced Mucosal MelanomaChina
-
Acceleron Pharma Inc. (a wholly owned subsidiary...TerminatedAdvanced Renal Cell CarcinomaUnited States
-
PfizerCompletedLung Neoplasms | Carcinoma, Non-small Cell LungUnited States, Germany
-
PfizerCompletedCarcinoma, Renal CellUnited States, Spain, Japan, Germany, Czechia, Russian Federation
-
Chinese University of Hong KongCompleted
-
AkesoRecruitingRenal Cell Carcinoma | First-line TreatmentChina
-
University of Wisconsin, MadisonPfizerCompletedSolid Malignancies | Metastatic Castrate-resistant Prostate CancerUnited States
-
Spanish Cooperative Group for the Treatment of...TerminatedColorectal CarcinomaSpain
-
Assistance Publique - Hôpitaux de ParisPfizerCompletedcT2a N0NxM0 Renal TumorFrance